show more articles
francs is the total of direct and indirect value added contributed by the pharmaceutical production and research activities. This corresponds to 9.3% of Switzerland's total economic output.
The chances of surviving a heart attack today are five times greater than in 1960.
Pharmacological and technological innovations will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research.
The pharmaceutical industry in Switzerland will also need attractive framework conditions in future, including legal certainty, open export markets and the availability of labour.
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2022
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives